These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

650 related articles for article (PubMed ID: 28041678)

  • 1. Update on the use of immunoglobulin in human disease: A review of evidence.
    Perez EE; Orange JS; Bonilla F; Chinen J; Chinn IK; Dorsey M; El-Gamal Y; Harville TO; Hossny E; Mazer B; Nelson R; Secord E; Jordan SC; Stiehm ER; Vo AA; Ballow M
    J Allergy Clin Immunol; 2017 Mar; 139(3S):S1-S46. PubMed ID: 28041678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology.
    Orange JS; Hossny EM; Weiler CR; Ballow M; Berger M; Bonilla FA; Buckley R; Chinen J; El-Gamal Y; Mazer BD; Nelson RP; Patel DD; Secord E; Sorensen RU; Wasserman RL; Cunningham-Rundles C;
    J Allergy Clin Immunol; 2006 Apr; 117(4 Suppl):S525-53. PubMed ID: 16580469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new intravenous immunoglobulin (BIVIGAM®) for primary humoral immunodeficiency.
    Wasserman RL
    Expert Rev Clin Immunol; 2014 Mar; 10(3):325-37. PubMed ID: 24527947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Replacement therapy with subcutaneous immunoglobulin in primary immunodeficiency in children].
    Pac M
    Pol Merkur Lekarski; 2011 Jun; 30(180):413-6. PubMed ID: 21751550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 7th International Immunoglobulin Conference: Poster presentations.
    Warnatz K; Ballow M; Stangel M; Bril V
    Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):162. PubMed ID: 25546805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Use and Therapeutic Potential of IVIG/SCIG, Plasma-Derived IgA or IgM, and Other Alternative Immunoglobulin Preparations.
    Späth PJ; Schneider C; von Gunten S
    Arch Immunol Ther Exp (Warsz); 2017 Jun; 65(3):215-231. PubMed ID: 27638480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant human hyaluronidase-facilitated subcutaneous immunoglobulin infusion in primary immunodeficiency diseases.
    Wasserman RL
    Immunotherapy; 2017 Sep; 9(12):1035-1050. PubMed ID: 28871852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunoglobulin Replacement Therapy for Primary Immunodeficiency.
    Sriaroon P; Ballow M
    Immunol Allergy Clin North Am; 2015 Nov; 35(4):713-30. PubMed ID: 26454315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating dose ratio of subcutaneous to intravenous immunoglobulin therapy among patients with primary immunodeficiency disease switching to 20% subcutaneous immunoglobulin therapy.
    Krishnarajah G; Lehmann JK; Ellman B; Bhak RH; DerSarkissian M; Leader D; Bullinger AL; Sheng Duh M
    Am J Manag Care; 2016 Oct; 22(15 Suppl):s475-s481. PubMed ID: 27849353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune globulin (human) 10 % liquid: a review of its use in primary immunodeficiency disorders.
    McCormack PL
    BioDrugs; 2013 Aug; 27(4):393-400. PubMed ID: 23703447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical experiences in primary and secondary immunodeficiencies and immune-mediated conditions using Gammanorm(®).
    Gardulf A
    Immunotherapy; 2016 May; 8(5):633-47. PubMed ID: 27020964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Choices in IgG replacement therapy for primary immune deficiency diseases: subcutaneous IgG vs. intravenous IgG and selecting an optimal dose.
    Berger M
    Curr Opin Allergy Clin Immunol; 2011 Dec; 11(6):532-8. PubMed ID: 21971330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunoglobulin therapy: methods of delivery.
    Ballow M
    J Allergy Clin Immunol; 2008 Nov; 122(5):1038-9. PubMed ID: 18804269
    [No Abstract]   [Full Text] [Related]  

  • 14. Subcutaneous immunoglobulin: rapid push vs. infusion pump in pediatrics.
    Shapiro RS
    Pediatr Allergy Immunol; 2013 Feb; 24(1):49-53. PubMed ID: 23331529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Subcutaneous immunoglobulin substitution and therapy].
    Gulácsy V; Maródi L
    Orv Hetil; 2011 Jan; 152(2):64-7. PubMed ID: 21177233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous immunoglobulin therapy: indications, potential side effects, and treatment guidelines.
    Suez D
    J Intraven Nurs; 1995; 18(4):178-90. PubMed ID: 7629638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subcutaneous immunoglobulin replacement therapy in patients with primary immunodeficiency in routine clinical practice: the VISPO prospective multicenter study.
    Vultaggio A; Azzari C; Milito C; Finocchi A; Toppino C; Spadaro G; Trizzino A; Baldassarre M; Paganelli R; Moschese V; Soresina A; Matucci A
    Clin Drug Investig; 2015 Mar; 35(3):179-85. PubMed ID: 25672929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein-glycan interactions as targets of intravenous/subcutaneous immunoglobulin (IVIg/SCIg) preparations.
    von Gunten S
    Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):151-2. PubMed ID: 25546801
    [No Abstract]   [Full Text] [Related]  

  • 19. Subcutaneous Immunoglobulins: A Promising Alternative for Immunomodulation?
    Sanchez-Ramon S; Corbi AL; Fidalgo AG; Dominguez-Soto A
    Curr Pharm Des; 2016; 22(41):6300-6305. PubMed ID: 27587200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 7th International Immunoglobulin Conference: Immunoglobulin in clinical practice.
    Shapiro RS; Borte M
    Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):86. PubMed ID: 25546773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.